Cancer Genetics and Implications for Clinical Management

The Surgical Clinics of North America
Nigel B JamiesonAndrew V Biankin

Abstract

There is now compelling evidence that the molecular heterogeneity of cancer is associated with disparate phenotypes with variable outcomes and therapeutic responsiveness to therapy in histologically indistinguishable cancers. This diversity may explain why conventional clinical trial designs have mostly failed to show efficacy when patients are enrolled in an unselected fashion. Knowledge of the molecular phenotype has the potential to improve therapeutic selection and hence the early delivery of the optimal therapeutic regimen. Resolution of the challenges associated with a more stratified approach to health care will ensure more precise diagnostics and enhance therapeutic selection, which will improve overall outcomes.

References

Jun 20, 1995·Proceedings of the National Academy of Sciences of the United States of America·M SchutteJ M Trent
Dec 8, 2004·Cancer Investigation·Howard SafranTeresa Kennedy
Sep 6, 2005·International Journal of Oncology·Peter BüchlerOscar J Hines
Aug 18, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenjiro KimuraKosei Hirakawa
Jan 4, 2007·Nature Genetics·Bing XiaJohan P de Winter
Jan 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey R InfanteMichael Goggins
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 29, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Gravalos, A Jimeno
Jul 24, 2008·Breast Cancer Research and Treatment·T ByrskiS A Narod
Jan 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Ketan S GajiwalaGeorge D Demetri
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josep Tabernero, Teresa Macarulla
Feb 26, 2010·Journal of Oncology·Katherine V Clark-KnowlesJohanne I Weberpals
Apr 24, 2010·Clinical Genetics·E P SlaterD K Bartsch
Jun 8, 2010·Nature Medicine·Nallasivam PalanisamyArul M Chinnaiyan
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Oct 29, 2010·The New England Journal of Medicine·Young Lim ChoiUNKNOWN ALK Lung Cancer Study Group
Jan 21, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria E ArcilaMarc Ladanyi
Feb 25, 2011·The New England Journal of Medicine·Carlo Gambacorti-PasseriniEnrico M Pogliani
Mar 9, 2011·Nature Medicine·Lynda ChinP Andrew Futreal
Mar 25, 2011·Science Translational Medicine·Lecia V SequistJeffrey A Engelman
Mar 30, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nigel B JamiesonKarin A Oien
Jun 7, 2011·Human Genetics·Andrew V Biankin, Thomas J Hudson
Jun 18, 2011·Nature Reviews. Genetics·Jesse S Boehm, William C Hahn
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffManuel Hidalgo
Feb 4, 2012·Genome Research·Emily A VucicWan L Lam
Feb 14, 2012·Nature Medicine·Takashi KohnoTatsuhiro Shibata
Mar 17, 2012·Proceedings of the National Academy of Sciences of the United States of America·Karen M MannNeal G Copeland
Apr 21, 2012·Science·Darryl Shibata
May 16, 2012·Cancer Discovery·Levi A Garraway, Pasi A Jänne
May 23, 2012·Cell·Serena Nik-ZainalUNKNOWN Breast Cancer Working Group of the International Cancer Genome Consortium
Jul 5, 2012·Genome Research·Nathan D DeesLi Ding
Aug 28, 2012·Science·Gopa IyerDavid B Solit
Sep 20, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Domenico CilibertoPierosandro Tagliaferri
Jan 16, 2013·Cell Reports·Ludmil B AlexandrovMichael R Stratton

❮ Previous
Next ❯

Citations

May 27, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·John G Nutt
Feb 6, 2019·Nature Reviews. Gastroenterology & Hepatology·Eric A CollissonAndrew V Biankin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Axon Guidance

Axon guidance is a complex neural developmental field that investigates mechanisms through which neurons send out axons to reach its target. Here is the latest research in this domain.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Related Papers

Current Opinion in Genetics & Development
David K ChangAndrew V Biankin
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Lucka Debevec, Andrej Debeljak
© 2021 Meta ULC. All rights reserved